Andrew Oh joined Rubius as Chief Financial Officer in December 2017. He brings to Rubius more than 20 years of experience in finance and the biopharmaceutical industry. Prior to joining Rubius, Andrew spent a decade as a portfolio manager at Leerink and Fidelity, investing in pharmaceutical and biotechnology companies. While at Fidelity, Andrew managed the Fidelity Select Pharmaceuticals Portfolio fund for seven years which was rated by Lipper as the number one global health/biotechnology fund based on his three and five year performance. In addition, Andrew served as Fidelity’s senior analyst covering global pharmaceutical companies, and worked in a similar role on Wall Street at prior firms, including Leerink and JPMorgan.
Andrew earned a B.A. in Biology from Washington University in St. Louis and holds a MBA from Northwestern’s Kellogg School of Management.